logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Jardine, Core Medica's application for an IPO on the Shanghai Stock Exchange has been "accepted."

date
06/11/2025
According to the Securities Times APP, on November 6th, the Shanghai Stock Exchange disclosed that Quanzhou Jia Deli Electronic Materials Co., Ltd. (Jia Deli) and Shenzhen Core Medical Technology Co., Ltd. (Core Medical) have had their IPO applications accepted by the Shanghai Stock Exchange.
Latest
3 m ago
Silence Therapeutics (SLN.US): The 2025 Q3 financial report achieved revenue of $159,000, down from $1.498 million, with an expected value of $4.41362 million; earnings per share were -$0.15, down from -$0.25, with an expected value of -$0.28.
3 m ago
Bank of England Governor Bailey: The risks brought by the second round of effects have not disappeared. Caution must be maintained to avoid the second round of effects.
3 m ago
Ministry of Industry and Information Technology: The total output value of 178 national high-tech zones accounts for 14.3% of the total GDP of the country.
4 m ago
Andrew Bailey, Governor of the Bank of England, stated that it is encouraging that the peak inflation rate in September was 0.2 percentage points lower than our forecast in August.
4 m ago
Crescent Biopharma (CBIO.US): The Q3 2025 financial report achieved revenue of 0 US dollars; earnings per share were -1.27 US dollars, lower than the expected value of -1.23 US dollars.
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.